Details for Patent: 9,993,476

Which drugs does patent 9,993,476 protect, and when does it expire?

Patent 9,993,476 protects VERQUVO and is included in one NDA.

This patent has eighty-seven patent family members in forty-six countries.

Summary for Patent: 9,993,476

Title:	Substituted 5-flouro-1H-pyrazolopyridines and their use
Abstract:	The present application relates to novel substituted 5-fluoro-1H-pyrazolopyridines, to processes for their preparation, to their use alone or in combinations for the treatment and/or prophylaxis of diseases, and to their use for producing medicaments for the treatment and/or prophylaxis of diseases, in particular for the treatment and/or prophylaxis of cardiovascular disorders.
Inventor(s):	Follmann; Markus (Cologne, DE), Stasch; Johannes-Peter (Solingen, DE), Redlich; Gorden (Bochum, DE), Ackerstaff; Jens (Dusseldorf, DE), Griebenow; Nils (Dormagen, DE), Kroh; Walter (Wuppertal, DE), Knorr; Andreas (Erkrath, DE), Becker; Eva-Maria (Wuppertal, DE), Wunder; Frank (Wuppertal, DE), Li; Volkhart Min-Jian (Velbert, DE), Hartmann; Elke (Wuppertal, DE), Mittendorf; Joachim (Wuppertal, DE), Schlemmer; Karl-Heinz (Wuppertal, DE), Jautelat; Rolf (Haan, DE), Bierer; Donald (Berlin, DE)
Assignee:	ADVERIO PHARMA GMBH (Schonefeld, DE)
Application Number:	15/348,545
Patent Claim Types: see list of patent claims	Use;

Drugs Protected by US Patent 9,993,476

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
Merck Sharp Dohme	VERQUVO	vericiguat	TABLET;ORAL	214377-001	Jan 19, 2021		RX	Yes	No						REDUCING THE RISK OF CARDIOVASCULAR DEATH AND HEART FAILURE (HF) HOSPITALIZATION FOLLOWING A HOSPITALIZATION FOR HF OR NEED FOR OUTPATIENT IV DIURETICS, IN ADULTS WITH SYMPTOMATIC CHRONIC HF AND EJECTION FRACTION LESS THAN 45%
Merck Sharp Dohme	VERQUVO	vericiguat	TABLET;ORAL	214377-002	Jan 19, 2021		RX	Yes	No						REDUCING THE RISK OF CARDIOVASCULAR DEATH AND HEART FAILURE (HF) HOSPITALIZATION FOLLOWING A HOSPITALIZATION FOR HF OR NEED FOR OUTPATIENT IV DIURETICS, IN ADULTS WITH SYMPTOMATIC CHRONIC HF AND EJECTION FRACTION LESS THAN 45%
Merck Sharp Dohme	VERQUVO	vericiguat	TABLET;ORAL	214377-003	Jan 19, 2021		RX	Yes	Yes						REDUCING THE RISK OF CARDIOVASCULAR DEATH AND HEART FAILURE (HF) HOSPITALIZATION FOLLOWING A HOSPITALIZATION FOR HF OR NEED FOR OUTPATIENT IV DIURETICS, IN ADULTS WITH SYMPTOMATIC CHRONIC HF AND EJECTION FRACTION LESS THAN 45%

Foreign Priority and PCT Information for Patent: 9,993,476

Foriegn Application Priority Data
Foreign Country	Foreign Patent Number	Foreign Patent Date
Germany	10 2010 021 637	May 26, 2010

International Family Members for US Patent 9,993,476

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Argentina	081628
Australia	2011257335
Australia	2011257336
Brazil	112012030010
Brazil	122020023470
Canada	2800697
Canada	2800709